BiotechTube

AZD5148

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridioides Difficile Infection

Conditions

Clostridioides Difficile Infection

Trial Timeline

Dec 10, 2025 → Jan 18, 2028

NCT ID
NCT07285213

About AZD5148

AZD5148 is a phase 2 stage product being developed by AstraZeneca for Clostridioides Difficile Infection. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07285213. Target conditions include Clostridioides Difficile Infection.

What happened to similar drugs?

0 of 4 similar drugs in Clostridioides Difficile Infection were approved

Approved (0) Terminated (1) Active (3)
🔄C.difficile vaccinePfizerPhase 3
❌Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄Ridinilazole + VancomycinSummit TherapeuticsPhase 3
🔄SER-109Seres TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07285213Phase 2Recruiting

Competing Products

7 competing products in Clostridioides Difficile Infection

See all competitors
ProductCompanyStageHype Score
AZD5148 + PlaceboAstraZenecaPhase 1
29
C.difficile vaccinePfizerPhase 3
47
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
29
Ridinilazole + VancomycinSummit TherapeuticsPhase 3
37
REC-3964Recursion PharmaceuticalsPhase 2
21
SER-109Seres TherapeuticsPre-clinical
16
SER-109Seres TherapeuticsPhase 3
30